Merck's Keytruda inches toward another biomarker-based OK with latest priority review
admin 7th April 2020 Uncategorised 0Merck & Co.’s immuno-oncology competitors have tried, so far fruitlessly, to use the investigational biomarker tumor mutational burden to help them win approvals. But regulators apparently like what they’re seeing from Merck where TMB is concerned.
More: Merck's Keytruda inches toward another biomarker-based OK with latest priority review
Source: fierce